Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The session is scheduled for September 16 at 8:30 a.m. EDT and will be webcast live, with a replay available on the Events & Presentations page of Helus Pharma’s investor relations website. The full press release can be accessed at https://ibn.fm/r0jfC.
The invitation to present at one of the healthcare investment community’s most closely watched conferences matters because it gives Helus Pharma a prominent platform to articulate its clinical progress and commercial strategy directly to institutional investors, analysts, and potential partners. For a clinical-stage company like Helus Pharma, whose commercial operating name is Cybin Inc., such visibility can influence perceptions of its pipeline, help attract capital, and shape expectations about the regulatory path for its lead candidates.
Helus Pharma is developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company’s goal is to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through NSAs that seek to provide durable improvements in mental health.
The company’s most advanced program, HLP003, is a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. It has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. That designation is significant because it is intended to expedite the development and review of drugs that may offer substantial improvement over existing therapies. HLP004, also a proprietary NSA, is in Phase 2 for generalized anxiety disorder. Together, these programs represent a late-stage pipeline that could potentially reshape treatment paradigms for two of the most common and debilitating mental health conditions.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. The company maintains an extensive research portfolio of investigational NSAs. For company updates and to learn more about Helus Pharma, visit www.helus.com. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.
The conference appearance comes as investors increasingly focus on mental health treatments that could offer alternatives to traditional antidepressants, which often take weeks to work and carry side effects. If Helus Pharma’s NSAs succeed in late-stage trials, they could provide durable improvements and a new mechanism of action. The fireside chat may therefore serve as a key moment for the company to differentiate its approach and build confidence ahead of anticipated data readouts.
BioMedWire (BMW), a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, disseminated the announcement. BMW is part of the Dynamic Brand Portfolio @ IBN, which provides wire solutions, editorial syndication to more than 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications. More information is available at https://www.BioMedWire.com. Full terms of use and disclaimers are posted at https://www.BioMedWire.com/Disclaimer.
